Myomin is a Chinese herbal supplement made by Chi’s Enterprise, Inc., marketed primarily as a natural way to reduce excess estrogen in the body. It contains a blend of three traditional herbs and is most commonly used by people dealing with estrogen-related conditions like uterine fibroids, ovarian cysts, and endometriosis. It is classified as a dietary supplement, not a medication, and has not been approved by the FDA to treat any disease.
What Myomin Contains
Each Myomin capsule (500 mg) is a blend of three herbs used in traditional Chinese medicine:
- Astragalus (334 mg): A root widely used in Chinese medicine, traditionally associated with immune support and energy.
- Curcuma zedoaria (333 mg): A plant related to turmeric, used in traditional medicine for its effects on circulation and inflammation.
- Cyperus rotundus (333 mg): Sometimes called nut grass, a plant traditionally used in Chinese and Ayurvedic medicine for menstrual and digestive complaints.
The product is sold as an “all-natural Chinese herbal blend” in bottles of 120 capsules. Chi’s Enterprise markets it as helping to maintain healthy hormone levels.
How It Supposedly Works
The central claim behind Myomin is that it acts as a natural aromatase inhibitor. Aromatase is an enzyme your body uses to convert testosterone and another hormone called DHEA into estrogen. When this conversion process goes into overdrive, a state sometimes called hyperaromatization, estrogen can accumulate beyond what the body needs. That excess estrogen is linked to the growth of fibroids, cysts, and endometrial tissue outside the uterus.
Pharmaceutical aromatase inhibitors are well-established drugs used in breast cancer treatment. Myomin’s proponents claim the herbal blend achieves a similar effect naturally, reducing aromatase activity and lowering estrogen levels without the side effects associated with prescription options. It’s worth noting that this mechanism has not been validated through the kind of large-scale, peer-reviewed clinical trials that pharmaceutical aromatase inhibitors have undergone.
Conditions It’s Used For
People typically seek out Myomin for estrogen-dominant conditions. The most common uses include uterine fibroids, ovarian cysts, endometriosis, and hormonal imbalances related to excess estrogen. Some practitioners in integrative and alternative medicine recommend it alongside other supplements.
Ovarian Cysts
One practitioner-reported case described an ovarian cyst clearing after two to three months of Myomin combined with iodide. A separate observational study gave Myomin to 85 women with ovarian cysts over three months. Of those, 44 had simple ovarian cysts, 40 had cysts related to endometriosis, and one had ovarian cancer. Details on the full outcomes of this study are limited in publicly available sources, and it was not published in a major peer-reviewed journal.
Uterine Fibroids
A study conducted in 2000 at Shanghai Medical School looked at 60 patients with uterine fibroids. When Myomin was used in combination with another Chi’s Enterprise product called Angiostop, the combination was reported as 69.2% effective for fibroids larger than 2.5 cubic centimeters, with an additional 19% of patients showing some improvement. These numbers come from a single study with a small sample size and no placebo control group, which limits how much weight they carry as evidence.
What the Evidence Actually Looks Like
The studies cited in support of Myomin are small, observational, and largely published in alternative medicine outlets like the Townsend Letter rather than in mainstream medical journals with rigorous peer review. None of them are randomized controlled trials, the gold standard for determining whether a treatment actually works. Most of the clinical reports come from individual practitioners describing their own patients’ outcomes, which makes it impossible to separate the supplement’s effects from natural fluctuations in these conditions over time.
This doesn’t necessarily mean Myomin is ineffective. The individual herbs in the formula do have documented biological activity in laboratory settings. But the gap between “these herbs have interesting properties in a lab” and “this supplement reliably treats fibroids in humans” is enormous, and Myomin has not crossed it with strong clinical data.
FDA Concerns
In 2018, the FDA issued a warning letter to Chi’s Enterprise, Inc. for violations related to current good manufacturing practices for dietary supplements. The warning focused on how the company manufactured, packaged, and labeled its products. This type of violation raises questions about quality control, consistency between batches, and whether each capsule reliably contains what the label says it does.
As a dietary supplement, Myomin does not require FDA approval before being sold. The FDA only intervenes after the fact if a product is found to be unsafe or if the manufacturer makes illegal drug claims. This regulatory framework means the burden of evaluating safety and efficacy falls largely on the consumer.
Practical Considerations
Myomin is widely available through online supplement retailers and some integrative health practitioners. Because it is positioned as an aromatase inhibitor, anyone taking hormone-sensitive medications, including birth control, hormone replacement therapy, or prescription aromatase inhibitors for cancer, should be aware of potential interactions. The herbal ingredients could theoretically alter hormone levels in ways that interfere with these treatments.
There is very little published data on side effects specific to Myomin. This absence of reported adverse effects is sometimes presented as evidence of safety, but it more accurately reflects the lack of systematic study. The individual herbs in the formula have long histories of use in traditional medicine, which provides some reassurance but is not the same as formal safety testing.
If you’re considering Myomin for fibroids, cysts, or another estrogen-related condition, it helps to understand that you’re working with a product supported by traditional use and a handful of small studies, not by the level of evidence behind conventional treatments for these conditions. That may be acceptable to you depending on your situation, but it’s a distinction worth knowing.